MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.

Researchers establish the first international criteria for standardized imaging of gliomas

Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and

January 3, 2024

Health care AI requires a new Hippocratic oath

It was no surprise when the Biden administration recently outlined in a broad executive order the challenges AI poses and what is needed to address

December 8, 2023

New definition of a human embryo proposed amid rapid scientific advances

When someone says the word embryo, what do you think of? Probably that picture you’ve seen a thousand times on a thousand different news articles:

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.